Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction

The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction. However, after prolonged inactivation of MYC in a conditional transgenic mouse model of Eμ-tTA/tetO-MYC T-cell acute lymphoblastic leukemia, some of the tumors recur, recapitulating what is frequently observed in human tumors in response to targeted therapies. Here we report that these recurring lymphomas express either transgenic or endogenous Myc, albeit in many cases at levels below those in the original tumor, suggesting that tumors continue to be addicted to MYC. Many of the recurring lymphomas (76%) harbored mutations in the tetracycline transactivator, resulting in expression of the MYC transgene even in the presence of doxycycline. Some of the remaining recurring tumors expressed high levels of endogenous Myc, which was associated with a genomic rearrangement of the endogenous Myc locus or activation of Notch1. By gene expression profiling, we confirmed that the primary and recurring tumors have highly similar transcriptomes. Importantly, shRNA-mediated suppression of the high levels of MYC in recurring tumors elicited both suppression of proliferation and increased apoptosis, confirming that these tumors remain oncogene addicted. These results suggest that tumors induced by MYC remain addicted to overexpression of this oncogene.

[1]  B. Amati,et al.  Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis. , 2000, Nucleic acids research.

[2]  Rainer Breitling,et al.  Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments , 2004, FEBS letters.

[3]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[4]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[6]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[7]  Dean W. Felsher,et al.  Cancer revoked: oncogenes as therapeutic targets , 2003, Nature Reviews Cancer.

[8]  L. Larsson,et al.  c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. , 2000, Blood.

[9]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[10]  J L Cleveland,et al.  The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Aster,et al.  c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. , 2006, Genes & development.

[12]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[13]  Adam A. Margolin,et al.  NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth , 2006, Proceedings of the National Academy of Sciences.

[14]  S. Blacklow,et al.  Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A. , 2009, Genes & development.

[15]  D. Felsher,et al.  The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. , 2010, Genes & development.

[16]  C. Dang,et al.  Translocations involving c-myc and c-myc function , 2001, Oncogene.

[17]  D. Felsher,et al.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. , 2003, Blood.

[18]  D. Felsher.  Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? , 2008, Cancer research.

[19]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[20]  S. Pelengaris,et al.  The many faces of c-MYC. , 2003, Archives of biochemistry and biophysics.

[21]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[22]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[23]  M. Bhasin,et al.  Notch1 Contributes to Mouse T-Cell Leukemia by Directly Inducing the Expression of c-myc , 2006, Molecular and Cellular Biology.

[24]  J. Nevins,et al.  Ras enhances Myc protein stability. , 1999, Molecular cell.

[25]  G. Evan,et al.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.

[26]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.

[27]  C. Sawyers,et al.  Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias , 2003, Oncogene.

[28]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[29]  L. Chodosh,et al.  Isoform-Specific Ras Activation and Oncogene Dependence during MYC- and Wnt-Induced Mammary Tumorigenesis , 2006, Molecular and Cellular Biology.

[30]  Dean W. Felsher,et al.  Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas , 2008, PloS one.

[31]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[32]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[33]  J. Settleman,et al.  Oncogenic K-ras “addiction” and synthetic lethality , 2009, Cell cycle.

[34]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[35]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[36]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[37]  John Calvin Reed,et al.  Bax is a transcriptional target and mediator of c-myc-induced apoptosis. , 2000, Cancer research.

[38]  R. Cardiff,et al.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.

[39]  H. Varmus,et al.  Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras , 2008, Proceedings of the National Academy of Sciences.

[40]  Robert B Boxer,et al.  Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. , 2004, Cancer cell.

[41]  Dean W. Felsher,et al.  Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation , 2007, Proceedings of the National Academy of Sciences.

[42]  E. Passegué,et al.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch , 2006, Proceedings of the National Academy of Sciences.

[43]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[44]  Jonathan Chernoff,et al.  Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2011 .

[45]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[46]  E. Haura,et al.  Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. , 2010, Biochemical pharmacology.

[47]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[48]  Kavya Rakhra,et al.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. , 2010, Cancer cell.

[49]  R. Cardiff,et al.  Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. , 2008, The Journal of clinical investigation.